Ji-In Kim

USPTO Granted Patents = 14 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 10)

Average Co-Inventor Count = 5.4

ph-index = 2

Forward Citations = 14(Granted Patents)

Company Filing History:

10 out of 21

Kadmon Corporation, LLC

Kadmon Corportion, LLC

patent

Years Active: 2010-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12030857 - Glucose uptake inhibitors (2024-07-09),

2. 11926596 - Inhibitors of Rho associated coiled-coil containing protein kinase (2024-03-12),

3. 11613531 - Inhibitors of RHO associated coiled-coil containing protein kinase (2023-03-28),

4. 11479533 - Inhibitors of Rho associated coiled-coil containing protein kinase (2022-10-25),

5. 11071735 - Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors (2021-07-27),

6. 10988484 - Glucose uptake inhibitors (2021-04-27),

7. 10696660 - Rho kinase inhibitors (2020-06-30),

8. 10273248 - Glucose uptake inhibitors (2019-04-30),

9. 10183931 - Rho kinase inhibitors (2019-01-22),

10. 10125144 - Rho kinase inhibitors (2018-11-13),

11. 9815820 - Rho kinase inhibitors (2017-11-14),

12. 7935719 - N-substituted-azacyclylamines as histamine-3 antagonists (2011-05-03),

13. 7820825 - N-substituted-azacyclylamines as histamine-3 antagonists (2010-10-26),

14. 7723368 - Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compounds for the inhibition of beta-secretase (2010-05-25),

Title: The Innovative Contributions of Ji-In Kim

Introduction

Ji-In Kim is a prominent inventor based in Princeton, NJ, known for his significant contributions to the field of biomedical research. With a total of 14 patents to his name, Kim has made remarkable strides in developing compounds that address critical health issues.

Latest Patents

Among his latest inventions are glucose uptake inhibitors, which provide compounds that modulate glucose uptake activity and cellular transport of glucose, particularly targeting GLUTS3, as well as GLUT1-14. These compounds are instrumental in treating various diseases, including cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic disorders. Another notable invention is the inhibitors of Rho associated coiled-coil containing protein kinase (ROCK1 and/or ROCK2), which includes methods for inhibiting these proteins to aid in disease treatment.

Career Highlights

Throughout his career, Ji-In Kim has worked with several reputable companies, including Kadmon Corporation and Wyeth. His work in these organizations has allowed him to further his research and development efforts in the biomedical field.

Collaborations

Kim has collaborated with notable colleagues, including Masha V Poyurovsky and Kevin G Liu, enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Ji-In Kim's innovative work in developing therapeutic compounds showcases his dedication to improving health outcomes. His contributions continue to influence the biomedical landscape significantly.

This text is generated by artificial intelligence and may not be accurate.